Description: Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermatitis. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, and acne and wart treatment. It has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The company was incorporated in 2009 and is based in Danderyd, Sweden.
Home Page: lipidor.se
Svärdvägen 13
Danderyd,
182 33
Sweden
Phone:
46 7 25 07 03 69
Officers
Name | Title |
---|---|
Mr. Ola Holmlund | Chief Executive Officer |
Mr. Olle Holmertz | Founder & Business Controller |
Mr. Anders Carlsson Ph.D. | Co-Founder, Senior Advisor & Chief Development Officer |
Dr. Bengt Herslöf Ph.D. | Co-founder & Senior Scientific Advisor |
Dr. Jan Holmbäck Ph.D. | Co-Founder & Chief Scientific Officer |
Dr. Gerhard Miksche Ph.D. | Co-Founder |
Ms. Charlotta Ekman | Chief Financial Officer |
Ms. Vibhu Rinwa | Chief Operating Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.1476 |
Price-to-Sales TTM: | 128.237 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 5 |